These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30616638)

  • 21. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
    Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
    Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
    Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Wu S; Wang J; Guo S; Chai S; Yang Z; Li L; Zhang Y; Ji L; Zhan S
    Clin Ther; 2015 Jan; 37(1):225-241.e8. PubMed ID: 25554560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
    Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.
    Zhao D; Liu H; Dong P
    Clin Exp Hypertens; 2020 Jul; 42(5):393-400. PubMed ID: 31610701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2014 Dec; 32(12):2296-304. PubMed ID: 25259547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.
    Wang W; Wei R; Huang Z; Luo J; Pan Q; Guo L
    Diabetes Metab Res Rev; 2023 Oct; 39(7):e3680. PubMed ID: 37356073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.